Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Martin A. Makary

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6091-4929; OpenAlex author ID A5004066994. Sources: ClinicalTrials.gov.

Their work

Papers
15
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 5 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper

Papers 15

  1. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Co-author DOI 10.1158/1078-0432.ccr-20-2974↗
  2. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04230-z↗
  3. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Co-author DOI 10.1007/s11605-018-3966-8↗
  4. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Co-author DOI 10.1038/s41379-019-0317-6↗
  5. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25288↗
  6. Metastatic Pancreatic Adenocarcinoma in a Patient With Chronic Calcific Pancreatitis and a Heterozygous SPINK1 c.194+2T>C Mutation. Co-author DOI 10.1097/mpa.0000000000001015↗
  7. Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreat… Co-author DOI 10.1097/pas.0000000000001148↗
  8. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? Co-author DOI 10.1097/sla.0000000000002672↗
  9. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. Co-author DOI 10.1097/sla.0000000000002925↗
  10. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Co-author DOI 10.1002/cam4.1104↗
  11. Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation. Co-author DOI 10.1016/j.pan.2016.06.006↗
  12. Modified Appleby Procedure for Pancreatic Adenocarcinoma: Does Improved Neoadjuvant Therapy Warrant Such an Aggressive Approach? Co-author DOI 10.1245/s10434-016-5303-3↗
  13. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. Co-author DOI 10.1007/s11605-012-1923-5↗
  14. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. Co-author DOI 10.1007/s11605-011-1665-9↗
  15. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2010.04.003↗

Trials 1

  1. Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma Principal investigator NCT01045941↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 10 shared papers, 2016–2021 · strength 0.73
  2. Christopher Lee Wolfgang · 11 shared papers, 2011–2020 · strength 0.69
  3. Matthew John Weiss · 9 shared papers, 2017–2021 · strength 0.67
  4. Ammar A. Javed · 5 shared papers, 2016–2020 · strength 0.36
  5. Ralph H. Hruban · 5 shared papers, 2017–2020 · strength 0.36
  6. Lei Zheng · 5 shared papers, 2017–2021 · strength 0.36
  7. Alex B. Blair · 5 shared papers, 2017–2021 · strength 0.35
  8. Joseph M. Herman · 7 shared papers, 2011–2021 · strength 0.35
  9. Daniel A. Laheru · 5 shared papers, 2016–2021 · strength 0.33
  10. Ding Ding · 4 shared papers, 2018–2021 · strength 0.31
  11. Richard Andrew Burkhart · 4 shared papers, 2018–2020 · strength 0.30
  12. Richard David Schulick · 5 shared papers, 2011–2021 · strength 0.24
  13. Anne Marie Lennon · 3 shared papers, 2016–2020 · strength 0.23
  14. Michael Goggins · 3 shared papers, 2016–2020 · strength 0.22
  15. Georgios Gemenetzis · 3 shared papers, 2018 · strength 0.21
  16. Vincent P. Groot · 3 shared papers, 2018 · strength 0.21
  17. Laura DeLong Wood · 3 shared papers, 2016–2018 · strength 0.21
  18. Elliot K. Fishman · 3 shared papers, 2017–2020 · strength 0.21
  19. Atif Zaheer · 2 shared papers, 2018–2020 · strength 0.17
  20. Alison P. Klein · 2 shared papers, 2019–2020 · strength 0.16
  21. Danielle Hutchings · 2 shared papers, 2018–2019 · strength 0.16
  22. Robert A. Moran · 2 shared papers, 2016–2018 · strength 0.14
  23. Vikesh K. Singh · 2 shared papers, 2016–2018 · strength 0.14
  24. Barish H. Edil · 3 shared papers, 2011–2021 · strength 0.13
  25. Timothy Michael Pawlik · 4 shared papers, 2011–2016 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.